Current status and limitations of immunotherapy for breast cancer
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 4 references indexed in Scilit:
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trialThe Lancet Oncology, 2019
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2018
- Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal CancerAnnals of Surgical Oncology, 2018
- CDK4/6 inhibition triggers anti-tumour immunityNature, 2017